Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Pharmaceuticals
Genentech will pay the German biotech firm BioNTech $310 million in up-front and near-term milestone payments to develop messenger RNA-based individualized cancer vaccines. BioNTech uses next-generation sequencing to identify antigens present in an individual patient’s tumor. The firm then develops mRNA vaccines targeting those antigens. “Unlike any medicine we have ever developed, virtually all cancer patients may potentially benefit from a custom-built cancer vaccine,” says James Sabry, global head of Genentech Partnering.
This article has been sent to the following recipient: